Menlo Park, Calif. – October 18, 2026 -- Antheia has received a conditional commitment from the U.S. Department of War's Office of Strategic Capital (OSC) for a direct, long-term loan of up to $80 million to expand domestic production of critical pharmaceutical ingredients.

The loan, together with additional private capital, would fund Antheia's U.S. manufacturing strategy. The company's advanced biosynthesis platform is the technology behind the planned onshoring effort.